<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668159</url>
  </required_header>
  <id_info>
    <org_study_id>BONITO 2015-090</org_study_id>
    <nct_id>NCT02668159</nct_id>
  </id_info>
  <brief_title>Pilot Study on Metabolic Effects of Fish Peptides and Vitamin D</brief_title>
  <acronym>BONITO</acronym>
  <official_title>Cardiometabolic Health Effects and Mechanisms of Action of Fish Nutrients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to investigate the effects and the mechanisms of action of&#xD;
      a fish peptide and vitamin D on glucose metabolism, insulin secretion, and cardiometabolic&#xD;
      risk profile in overweight men. Transcriptomic and metabolomic approaches will be used to&#xD;
      study the acute physiological effects of fish nutrients and to discover gene/metabolite&#xD;
      networks that underlie these effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sedentary lifestyle and excess calorie intake have contributed to a dramatic increase in the&#xD;
      occurrence of obesity, metabolic syndrome (MetS), type 2 diabetes (T2D) and cardiovascular&#xD;
      disease (CVD) The first step in reducing the excessive CVD risk associated with the presence&#xD;
      of the MetS is the adoption of a healthier lifestyle. A balanced diet, including&#xD;
      high-nutritive and low-energy foods such as fish, is an important component of a healthy&#xD;
      diet. Fish is a major source of n-3 PUFA, high-quality protein, and other essential nutrients&#xD;
      such as vitamin D. Fish consumption may therefore improve the components of the MetS and&#xD;
      reduce the incidence of T2D and CVD in obese subjects.The foundation of this project stems&#xD;
      from the well-recognized fact that few Canadians meet the weekly dietary recommendation for&#xD;
      fish consumption (i.e. 2 servings/week) and thus intakes of both n-3 polyunsaturated fatty&#xD;
      acid (PUFA) and fish protein are low in the general population, and even lower in obese&#xD;
      subjects. Since some people simply dislike fish and because certain types of fish contain&#xD;
      toxic contaminants, including heavy metals and environmental pollutants, fish consumption&#xD;
      remains low. Therefore, dietary choices limit intake of its key nutrients, thus increasing&#xD;
      risk for MetS, T2D and CVD. Also, fish is one of the richest food sources of dietary vitamin&#xD;
      D which may also contribute to the health benefits of fish consumption. Indeed, it is&#xD;
      currently estimated that ∼40% of Canadians have low serum 25-hydroxyvitamin D [25(OH)D]&#xD;
      concentrations (≤50 nM) and that ∼70% are below 75 nM. In addition, obesity is an important&#xD;
      risk factor for low serum 25(OH)D.The main objective of this study is to investigate the&#xD;
      acute effects and mechanisms of action of fish peptide and vitamin D on glucose metabolism,&#xD;
      parameters of insulin sensibility and secretion, and cardiometabolic risk profile in&#xD;
      overweight men.&#xD;
&#xD;
      A four-arm randomized crossover design will be used to test the metabolic effects of&#xD;
      consuming prior to a 3h-oral glucose tolerance test (OGTT), supplements containing either&#xD;
      fish peptide (3 grams), vitamin D3 (1000 IU), a combination of fish peptide + vitamin D3 or a&#xD;
      placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum glucose area under the curve (Glucose AUC)</measure>
    <time_frame>0-180 min</time_frame>
    <description>The area under the curve for serum glucose concentration is calculated from 0-180min after 75g glucose is ingested</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum insulin area under the curve (Insulin AUC)</measure>
    <time_frame>0-180 min</time_frame>
    <description>Area under the curve for serum insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-peptide area under the curve (C-peptide AUC)</measure>
    <time_frame>0-180 min</time_frame>
    <description>Area under the curve for serum C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglycerides concentrations</measure>
    <time_frame>-15, 0, 15, 30, 60, 120, 180 min post 75g glucose</time_frame>
    <description>changes in the triglycerides concentration at each time point of the OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 25(OH)D concentrations</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in the 25(OH)D concentration measured before each OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk profile in serum</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in cardiometabolic profile measured in serum before each OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profile</measure>
    <time_frame>4 weeks</time_frame>
    <description>peripheral blood mononuclear cells (PBMCs) gene expression</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Prediabetes</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Fish peptide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish peptide + Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish peptide supplement</intervention_name>
    <description>6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT</description>
    <arm_group_label>Fish peptide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D supplement</intervention_name>
    <description>1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish peptide + Vitamin D3 supplements</intervention_name>
    <description>6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT</description>
    <arm_group_label>Fish peptide + Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>7 tablets of placebos administered prior to one the OGTT</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  overweight (BMI 25-40 kg/m2)&#xD;
&#xD;
          -  fasting triglycerides ≥ 1.5 mmol/L&#xD;
&#xD;
          -  fasting insulin ≥ 60 pmol/L&#xD;
&#xD;
          -  non-smoking&#xD;
&#xD;
          -  stable weight in the past 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  chronic diseases&#xD;
&#xD;
          -  taking drugs that could affect glucose or lipid metabolism&#xD;
&#xD;
          -  taking dietary supplements or natural health products&#xD;
&#xD;
          -  major surgery 3 months prior to the study&#xD;
&#xD;
          -  fish or seafood allergy&#xD;
&#xD;
          -  lactose intolerance&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Claude Vohl</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instute of Nutrition and Functional Foods, Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Nutrition and Functional Foods (INAF), Laval University</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Marie-Claude Vohl</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

